Last reviewed · How we verify
CD07805/47 gel
CD07805/47 gel is a Retinoid Small molecule drug developed by Galderma R&D. It is currently in Phase 3 development for Acne vulgaris.
CD07805/47 gel is a topical retinoid that modulates skin cell differentiation and reduces inflammation for acne treatment.
CD07805/47 gel is a topical retinoid that modulates skin cell differentiation and reduces inflammation for acne treatment. Used for Acne vulgaris.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CD07805/47 gel |
|---|---|
| Sponsor | Galderma R&D |
| Drug class | Retinoid |
| Target | Retinoid receptors (RAR/RXR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
As a retinoid compound formulated as a gel, CD07805/47 works by binding to retinoid receptors in skin cells, promoting cell turnover and reducing comedone formation. It also exhibits anti-inflammatory properties that help reduce acne-associated inflammation and bacterial colonization on the skin surface.
Approved indications
- Acne vulgaris
Common side effects
- Skin irritation
- Erythema
- Dryness
- Photosensitivity
Key clinical trials
- Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea (PHASE3)
- Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea (PHASE2)
- Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea (PHASE3)
- Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea (PHASE3)
- Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea (PHASE2)
- MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea. (PHASE4)
- Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea (PHASE3)
- Effect of CD07805/47 Gel in Rosacea Flushing (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD07805/47 gel CI brief — competitive landscape report
- CD07805/47 gel updates RSS · CI watch RSS
- Galderma R&D portfolio CI
Frequently asked questions about CD07805/47 gel
What is CD07805/47 gel?
How does CD07805/47 gel work?
What is CD07805/47 gel used for?
Who makes CD07805/47 gel?
What drug class is CD07805/47 gel in?
What development phase is CD07805/47 gel in?
What are the side effects of CD07805/47 gel?
What does CD07805/47 gel target?
Related
- Drug class: All Retinoid drugs
- Target: All drugs targeting Retinoid receptors (RAR/RXR)
- Manufacturer: Galderma R&D — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Acne vulgaris
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing